Boston Scientific has entered into a licensing and development agreement with Surgi-Vision for access to the latter’s MRI-safe technology.
Under the agreement, Boston Scientific said it will gain access to Surgi-Vision's development capabilities and will obtain a license to Surgi-Vision's intellectual property for potential use in its implantable cardiac devices.
The financial terms of the agreement were not disclosed.
The two companies said they will work jointly to develop a commercial application of Surgi-Vision's technology.
The Natick, Mass.-based Boston Scientific and the Baltimore-based Surgi-Vision also entered into a separate licensing and development agreement in the area of neuromodulation in December 2005.